Harlan Contract Research Services Cytotest Cell Research Selected for Membership in EU-NETVAL
News Aug 12, 2013
EU-NETVAL provides support for the European Union Reference Laboratory for Alternatives to Animal Testing (EURL ECVAM) to develop methods to reduce, refine or replace animals used for scientific purposes.
“Being in the initial group of laboratories acknowledges the expertise of our scientists as well as our continuous work in and support for alternative in vitro methodologies, including our participation in EU validation projects in the past,” said Dr. Albrecht Poth, deputy managing director and scientific advisor for Harlan CRS Cytotest Cell Research. “We are honored to have Harlan CRS play a role in this important research evolution.”
The aim of EURL ECVAM is to promote the scientific and regulatory acceptance of non-animal tests and to coordinate the independent evaluation of tests for specific purposes. Harlan CRS Cytotest Cell Research will contribute to the development of guidance documents, procedures, training materials and collaboration tools that facilitate the development, validation and acceptance of alternative methods.
Harlan CRS began as a regional provider of research models and services in the Midwestern U.S. more than 70 years ago and today is a global provider of those services.
“We have been researching new test systems in the fields of alternative toxicology, medical devices and genetic toxicology for several years,” Dr. Poth said. “Our hope is that someday we can eliminate animal testing entirely.”
Tight junctions are multi-protein complexes that serve as barriers in epithelial tissues such as the skin or lining of the gut. Loss of a specific tight junction barrier protein, claudin 18, occurs in the majority of gastric cancer patients and is correlated with poor prognosis in patients with advanced gastric cancer.READ MORE